# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹352 Cr** (+19% YoY) * Consolidated Revenue: ₹351.5 Cr (+19% YoY) * **EBITDA:** **₹57 Cr** (+28% YoY) * Consolidated EBITDA: ₹56.6 Cr (+28% YoY), margin at 16.1% * PAT: ₹31 Cr (+5% YoY), margin maintained at 8.8% ## B. Revenue Growth * **Strong Annualized Momentum:** Business demonstrates robust scale-up, with quarterly revenue growth implying **₹240 Cr in annualized expansion** from Jammu and core operations. * **Segment Strength:** Consolidated growth driven by **strong performance in both CDMO and Branded Generics** segments. ## C. EBITDA & Margins * **Profitability Leverage:** EBITDA expanded at a faster rate than revenue, signaling operating leverage and **gross margin improvement** despite cost pressures. * **Cost Discipline:** Operating costs improved sequentially even as revenue rose by **₹50–60 Cr Q-on-Q**, aided by semi-variable cost structure. ## D. Profit After Tax * **Margin Resilience:** PAT margin held steady at 8% despite **higher depreciation and finance costs**, reflecting underlying earnings quality. ## E. Cash Flow Position * **Expense Composition:** Consolidated other expenses of **₹40 Cr** include variable and fixed costs from Jammu, Univentis, and Sharon, with future trajectory linked to growth and cost behavior. --- # 2. Segment & Revenue Mix ## A. Key Figures * CDMO Revenue: ₹249.5 Cr (71% of total) (+8%) * Branded Generics Revenue: **₹101.2 Cr** (+59%) ## B. CDMO Performance * **Strategic Reorganization:** Business restructured into CDMO and branded generics verticals to improve focus, operational efficiency, and strategic clarity. * **CDMO Scale & Traction:** CDMO remains dominant revenue driver with robust client base of **300+ global pharma partners** and a diversified portfolio of **3,700+ products** across dosage forms. * **Operational Resilience:** Stand-alone CDMO operations in Jammu and Baddi grew 5% YoY despite pricing pressure, reflecting underlying manufacturing strength. ## C. Branded Generics Growth * **Explosive Growth Trajectory:** Branded generics delivered near-sixty percent annual growth, driven by expanded geographic reach and deeper domestic market penetration. * **Export-Led Momentum:** Surge in branded generics exports supported by Jammu incentives and strong performance from **Univentis Medicare**, the company’s dedicated trade generics arm. ## D. Domestic vs Export * **Manufacturing-Led Export Expansion:** Rising export revenues fueled by increased output from Baddi and Jammu facilities, leveraging expanded capacity to meet international demand. * **Enhanced Reporting Clarity:** Segment reclassification improves transparency and aligns reporting with strategic priorities, aiding investor assessment. --- # 3. Manufacturing & Ramp-Up ## A. Key Figures * **Jammu Revenue (Current Quarter):** **₹60 Cr** (includes transferred products) * **Jammu Plant Investment:** **₹480 Cr** (CGMP-compliant, fully automated) * **Jammu EBITDA Performance:** Near breakeven in Q2 with **₹1 Cr loss** * **Max Annual Revenue Potential (Jammu):** **₹1,500–2,000 Cr** ## B. Jammu Facility Progress * **On-Track Ramp-Up:** Greenfield Jammu facility commercialized in Jan-25 with strong CDMO interest and branded generics demand supporting **swift scale-up momentum**. * **Revenue Outlook Under Review:** Initial ₹400 Cr annual projection under pressure due to **~20% decline in API prices**, though incremental ₹400 Cr contribution remains the target. * **Operational Progress:** Jammu has resolved cephalosporin capacity constraints and achieved near EBITDA breakeven in its second quarter, signaling **improving cost efficiency** despite ramp-up complexities. * **Long-Term Margin Trajectory:** Margins expected to expand meaningfully as operations stabilize, though near-term guidance remains withheld due to onboarding variability. ## C. Baddi Plant Transition * **Strategic Repositioning:** Cepha business fully shifted to Jammu, enabling Baddi to focus on export markets and driving **rapid export revenue growth**. * **Temporary Revenue Disruption:** Baddi sales temporarily down due to product transfers, with normalization expected within **1–2 quarters**. ## D. Capacity Utilization * **High Embedded Optionality:** Current asset utilization below **5%** highlights significant under-levered capacity, with long-term revenue potential of ₹1,500–2,000 Cr signaling substantial scalability. --- # 4. Product & Therapeutic Areas ## A. API Pricing Impact * **Limited Revenue Exposure:** Anti-infectives contribute a minor share to overall revenue, cushioning the impact of API price declines. * **Pricing Pressure:** API price reductions are exerting a **slight negative effect** on total revenue, though not material at current levels. --- # 5. Client & Market Expansion ## A. Global Client Base * **Core Growth Strategy:** Focus on gaining wallet share from existing clients by leveraging strong relationships with **top domestic Indian companies** and expanding product onboarding at Jammu via registrations in ROW and regulated markets. * **Client-Specific Dynamics:** Product transfers require **client consent**, indicating a collaborative model; shift underway in domestic cephalosporin operations. ## B. ROW Market Traction * **Export Momentum:** Robust international growth fueled by presence across **10–15 therapeutic categories**, with primary contribution from **Rest of World (ROW) markets**. ## C. Regulatory Registrations * **Industry Consolidation Catalyst:** Upcoming **Schedule M implementation** could trigger exit of smaller players unable to comply, potentially creating market share opportunities for compliant firms. --- # 6. Pricing & Supply Risks ## A. Key Figures * **Potassium Clavulanate Price:** **₹13,000** (from ₹18,500) ## B. API Price Volatility * **Cost-Plus Model Shields Margins:** Company insulates profitability through **cost-plus pricing** on APIs, mitigating impact of commodity-like volatility. * **Supply-Driven Price Erosion:** Sharp decline in potassium clavulanate prices driven by **post-COVID capacity expansion** and oversupply in key intermediates (Pen G, 7ACA). ## C. Oral Liquid Constraints * **Segment-Specific Bottleneck:** Oral liquid capacity is currently constrained, creating operational imbalance despite unconstrained solid dosage output. * **Supply Chain Uncertainty:** Export continuity from Baddi plant remains uncertain amid domestic business transition; backlog visibility is limited. --- # 7. Guidance & Outlook ## A. Revenue Projections * **Growth Momentum:** On track toward annual revenue target, supported by product expansion, geographic reach, and manufacturing scale. * **Sequential Growth Intent:** Company expects **quarter-on-quarter utilization improvement**, signaling confidence in demand and execution. * **Guidance Uncertainty:** Full impact of API pricing remains unclear; prior guidance contingent on **price stabilization**. ## B. Breakeven Timeline * **Jammu Ramp-Up Progress:** Current quarterly revenue of ₹60 Cr aligns with operational breakeven; **PAT positivity expected by year-end**. * **No Near-Term Financial Guidance:** Management refrains from firm forecasts due to ramp-up volatility and market uncertainties. ## C. Incentive Dependency * **GST Rate Sensitivity:** Incentive achievement highly dependent on GST structure—**lower rates require significantly higher sales volume** to offset. * **Incentive Accounting & Timing:** ₹60–65 Cr recognized on accrual basis, pending GST authority approval, with **1–2 quarter cash flow lag expected**. * **Utilization Implication:** At full revenue potential, current incentives imply a modest **10–15% utilization rate**, suggesting upside headroom.